OpportunityTitle: FY15 Peer Reviewed Cancer Translational Team Science Award
Description: The FY15 PRCRP Translational Team Science Award (TTSA) is new for FY15 and supports translational correlative studies associated with an existing or completed clinical trial that could lead to a future clinical application or the next-phase clinical trial. The ultimate goal of translational research is to move observations forward into clinical application. The intent of the TTSA is to leverage information from existing or completed clinical trials to address knowledge gaps in resulting outcomes. Studies may involve tissue or biopsy procurement or utilization of existing tissue sources. Of particular interest are studies investigating the differences in prognosis and treatment with respect to primary nodal status and/or the presence of metastatic disease; research on precursor lesions and the relationship to prevention and potential outcomes; investigations into tumor heterogeneity (e.g., genetic, epigenetic, immunological) and its association to the tumor microenvironment; and, studies on patient-reported outcomes and quality of life associated with treatment. The TTSA supports preclinical studies in animal models and human subjects and human anatomical substances. Accordingly, development or use of relevant preclinical models may be included. The TTSA is not intended to support high throughput screenings, sequencing, etc. Funding for the clinical trial is not allowed. The TTSA requires that multiple investigators jointly design a single project, with comparable levels of intellectual input from each Principal Investigator (PI). However, each partner will be recognized as a PI, submit a separate application (even if the partners are at the same organization), and receive an individual award. The research project must be supported by the unique expertise, experience, and abilities of each PI; and it must clearly define the translational components that will facilitate and accelerate progress in a way that could not be accomplished through independent efforts. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PIs will be identified as Partnering PIs. Initiating and Partnering PIs each have different submission requirements, as described in Section II; however, all PIs should contribute significantly to the development of the proposed research project. If recommended for funding, each PI will receive his or her own award. Multidisciplinary projects are encouraged, and at least two organizations must be included in the application. Applications should include clearly stated plans for interactions among all PIs and organizations involved. The plans must include communication, coordination of research progress and results, and data transfer. Additionally, applications must provide an intellectual property plan to resolve potential intellectual and material property issues and to remove institutional barriers that might interfere with achieving high levels of cooperation to ensure the successful completion of this award. Important aspects of the Translational Team Science Award are as follows: &#8226; Collaboration: The success of the project depends on the unique skills and contributions of each collaborator. At least three and up to five Principal Investigators across at least two institutions must partner in one overarching study in one of the required FY15 PRCRP Topic Areas. At least one early-career investigator and/or one military/VA investigator must be included as an equal partner in the research offering both intellectual investment and research effort. &#9675; An early-career investigator is defined as an investigator within 10 years after completion of a terminal degree (doctorate or any medical degree), excluding time spent in medical residency or during family medical leave. &#9675; A military/VA investigator is an investigator defined as active duty, active reserve, active duty detailed to agencies outside of the DoD, etc. The military/VA investigator should have a substantial role in the research and should not be included only for access to active duty military and/or VA populations (see below). &#8226; Translational Aspect: The application should provide evidence for the reciprocal transfer of ideas between basic and clinical science and vice versa in developing and implementing the research plan. Translational research should include correlative studies based on clinical trial outcomes, an ongoing clinical trial (Funding for the clinical trial is not allowed.), or translational research. The application should demonstrate how the study will leverage information from existing or completed clinical trials to address knowledge gaps in resulting outcomes.
GrantorContactEmailDescription: CDMRP Help Desk
GrantorContactText: Phone:  301-682-5507 &lt;br/&gt;Email:  help@eBRAP.org